Pharmacokinetics and pharmacodynamics of oral insulin ( ORMD ‐0801) in healthy subjects: A phase I study using hyperinsulinaemic‐euglycaemic clamp
Diabetes, Obesity and Metabolism · 2025-12 · 27 (12) · 6905-6913
DOI: 10.1111/dom.70089 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.09.2025. Verfasst von Yufei Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Insulin, Hypoglycemic Agents, Blood Glucose. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Hefei Tianhui Biotechnology Co., Ltd.
Abstract (Originalsprache)
Aims
To characterise the pharmacokinetic (PK) and pharmacodynamic (PD) properties of an oral insulin formulation (ORMD‐0801) in healthy subjects. Materials and Methods In this phase I hyperinsulinaemic‐euglycaemic clamp study with open‐label, randomised, crossover design, 20 healthy Chinese male subjects were randomised to receive either oral ORMD ‐0801 (8 or 16 mg), followed by subcutaneous ( SC ) insulin (5 IU , Tianmailin®) or vice versa. PK and PD parameters were evaluated by assessing changes in plasma insulin levels and glucose infusion rate ( GIR ) during an 11‐h clamp procedure.
Results
For 16 mg oral versus SC insulin, maximum GIR (GIR max ) was 3.87 ± 1.08 versus 3.51 ± 0.52 mg/kg/min, and area under the glucose infusion rate curve from 0 to 11 h (AUC GIR0–11h ) was 26.98 ± 10.69 versus 23.74 ± 9.04 h·mg/kg/min. For 8 mg oral versus SC insulin, GIR max was 3.86 ± 1.25 versus 5.41 ± 3.05 mg/kg/min, and AUC GIR0–11h was 27.07 ± 8.43 versus 29.95 ± 7.70 h·mg/kg/min. SC‐equivalent doses were 6.53 ± 3.97 IU (16 mg) and 4.62 ± 1.13 IU (8 mg), respectively. PK analysis showed area under the insulin concentration–time curve from zero to infinite (AUC Ins0‐∞ ) of 5.47 ± 3.17 versus 7.50 ± 2.37 h·ng/mL for 16 mg oral versus SC insulin, and 4.86 ± 2.89 versus 7.85 ± 2.02 h·ng/ mL for 8 mg oral versus SC insulin, with relative bioavailability of 0.53 ± 0.25% and 0.94 ± 0.77%.
Conclusions
This study comprehensively describes the PK/PD characteristics of ORMD‐0801 in healthy subjects and provides a basis for future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospi…
- Medical Affairs Department, Hefei Tianhui Biotechnology Co., Ltd, Hefei, China.
ORCID-Profile: Yufei Chen, Yifei Zhang, Weiqing Wang
Förderung
- Hefei Tianhui Biotechnology Co., Ltd
Zitieren
APA
Chen, Y., Hu, Z., Zhang, Y., Ma, M., Lv, Q., Zhou, J., Wang, J., Shao, T., Shi, J., Zhou, Y., Lu, J., Sheng, H., Gao, Y., Ning, G., & Wang, W. (2025). Pharmacokinetics and pharmacodynamics of oral insulin ( ORMD ‐0801) in healthy subjects: A phase I study using hyperinsulinaemic‐euglycaemic clamp. Diabetes, Obesity and Metabolism, 27(12), 6905-6913. https://doi.org/10.1111/dom.70089
Vancouver
Chen Y, Hu Z, Zhang Y, Ma M, Lv Q, Zhou J, et al. Pharmacokinetics and pharmacodynamics of oral insulin ( ORMD ‐0801) in healthy subjects: A phase I study using hyperinsulinaemic‐euglycaemic clamp. Diabetes, Obesity and Metabolism. 2025;27(12):6905-6913. doi:10.1111/dom.70089
BibTeX
@article{Chen2025,
author = {Chen, Yufei and Hu, Zhuomeng and Zhang, Yifei and Ma, Ming and Lv, Qing and Zhou, Jie and Wang, Jiayi and Shao, Ting and Shi, Jia and Zhou, Yingxia and Lu, Jiangjie and Sheng, Haiyuan and Gao, Ya and Ning, Guang and Wang, Weiqing},
title = {Pharmacokinetics and pharmacodynamics of oral insulin ( ORMD ‐0801) in healthy subjects: A phase I study using hyperinsulinaemic‐euglycaemic clamp},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {12},
pages = {6905--6913},
doi = {10.1111/dom.70089}
}
EUVIMED